4081472

4.0 <u>510(k) Summary</u>

Date: May 19, 2008

Sponsor of the 510(k)

AngiodDynamics, Inc.
603 Queensbury Ave
Queensbury, NY 12801

Establishment Registration number 1319211

Contact: Brian Kunst, Vice President, Regulatory Affairs and Quality Assurance

518-798-1215, x1123

Device Identification:

Proprietary Name:

SmartPort CT Series Port Access Systems

Common Name:

Vascular access port

Classification Name:

Subcutaneous, implanted, intravascular infusion port &

catheter

Classification Number:

21 CFR §880.5965

Classification Panel:

General Hospital

Product Code:

LJT

Regulatory Class:

II

Legally marketed device to which equivalence is claimed:

AngioDynamics SmartPort CT MP

510(k) K072375

AngioDynamics SmartPort CT

510(k) K062414

Horizon Medical Vortex Ports

510(k) K905841, K953529, K010189, K032557

Intended Use / Indications

The SmartPort CT Port Access System is indicated for any adult patient requiring repeated access of the vascular system or other selected body site, for the delivery of medications, nutritional supplementation, fluids, blood, blood products, and sampling of blood.

The SmartPort CT Series ports are also indicated for power injection of CT contrast media.

Vortex	CT	51	$\theta(k)$

Device Description

The SmartPort CT Series ports are Titanium or plastic, single or dual ports with a self sealing silicone rubber septum designed to maintain integrity after punctures with a non-coring needle. The port has a hollow area, or reservoir, under the septum through which fluid passes during infusion or aspiration.

The Vortex design features a proprietary reservoir with rounded walls giving it a toroidal shape. The outlet stem is located tangential to the reservoir wall allows fluid to pass between the reservoir and the catheter.

The SmartPort CT Series port systems offers models with catheters from 6.6FR to 12FR. The catheters contain radiopacifiers and have depth markings.

Question	YES	NO
Is the device intended for prescription use (21 CFR 801 Subpart D)? ^A	X	
Does the device contain components derived from a tissue or other biologic source?		X
Is the device provided sterile?	х	1.4
Is the device intended for single use?	X	
Is the device a reprocessed single use device?		Х
Does the device contain a drug?		Х
Does the device contain a biologic?		х
Does the device use software?		Х
Does the submission include clinical information?		Х
Is the device implanted?	X	

Vortex CT 510(k)	Confidential	Page 12 of 39
May 19, 2008		
		· -·-

Device comparison table

	AngioDynamics	AngioDynamics SmartPort	AngioDynamics SmartPort	RITA Medical Systems
	SmartPort CT Series	CT MP	CT	(formerly Horizon Medical
	Vortex Ports	K072375	K062414	Products)
				K905841, K953529,
				K010189, K032557
Intended use, power	Maximum 3 ml/sec or 5 ml/sec	Maximum 3 ml/sec injection rate	Maximum 5 ml/sec injection rate	Not indicated for power
injection	injection rate of contrast dye injected at up to 300 psi	of contrast dye injected at up to 300 psi.	of contrast dye injected at up to 300 psi.	injection
Design	Port system with attachable	Port system with attachable	Port system with attachable	Port system with attachable
	catheter	catheter, single.	catheter, single.	catheter, single or dual.
Port Material	Titanium or Plastic	Titanium	Titanium	Titanium or Plastic
Catheter Material	Polyurethane or Silicone	Polyurethane	Polyurethane or Silicone	Polyurethane or Silicone
Catheter Size	6.6-12 FR	5 FR	7.5-9.6 FR	6.6-12 FR
Shape	Round port system with tangential outlet	Round port system with tangential outlet	Round port system with tangential outlet	Round port system with tangential outlet
Septum Material	Silicone	Silicone	Silicone	Silicone
Pressure withstand, dynamic	300 PSI	300 PSI	300 PSI	Not Rated
Needles used for Access	19 or 20 Ga power injectable infusion set	19 or 20 Ga power injectable infusion set	19 or 20 Ga power injectable infusion set	19 or 20 Ga infusion set

Page 13 of 39

Confidential

Vortex CT 510(k) May 19, 2008



SEP 2 3 2008

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Mr. Brian Kunst ANGIODYNAMICS, Incorporated 603 Queensbury Avenue Queensbury, New York 12804

Re: K081472

Trade/Device Name: SmartPort CT Series Port Access System

Regulation Number: 880.5965

Regulation Name: Subcutaneous, Implanted, Intravascular Infusion Port and Catheter

Regulatory Class: II Product Code: LJT Dated: August 27, 2008 Received: August 29, 2008

Dear Mr. Kunst:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Chiu S. Lin, Ph. D Division Director

Division of Anesthesiology, General Hospital,
Infection Control and Dental Devices
Office of Device Evaluation

Center for Devices and Radiological Health

Indications for Use

510(k) Number (if known):

Device	Name:	<u>SmartPort</u>	CT Series Port	Access Sy	<u>stem</u>		
Indicati	ons for U	Jse:					
repeate	ed access	s of the vas	Port Access Sy cular system fo lood, blood pro	r the deli	very of med	ications, nutri	
contras	st media	at a maxim	Port Access Sy num infusion ra le infusion sets.				,
Subpart C)	(Pa	Ise <u>X</u> urt 21 CFR 80	1 Subpart D)			`	CFR 807
(PLEASE DC	O NOT W		OW THIS LINE ence of CDRH, O				IF NEEDED)
	Divis Infec	sion Sign-Of sion of Anest	~~~	ral Hospita			